Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.32 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24468279 | 0.82 | TRPV3 (0.30) | P2RX3P2RX2 | |
| SCHEMBL30841894 | 0.82 | TRPV3 (0.30) | P2RX3P2RX2 | |
| SCHEMBL24468103 | 0.81 | P2RX3 (0.33) | P2RX3P2RX2 | |
| SCHEMBL30841925 | 0.81 | P2RX3 (0.33) | P2RX3P2RX2 | |
| SCHEMBL24468261 | 0.81 | TLR7 (0.37) | P2RX3P2RX2PTGS2 | |
| SCHEMBL30841907 | 0.81 | TLR7 (0.37) | P2RX3P2RX2PTGS2 | |
| SCHEMBL7992615 | 0.79 | FNTA (0.35) | — | |
| SCHEMBL7999655 | 0.79 | KCNK13 (0.33) | — | |
| SCHEMBL9925511 | 0.79 | TRPV4 (0.34) | — | |
| SCHEMBL24468105 | 0.77 | TRPV3 (0.38) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4251624-B1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20240101570-A1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC. | 2024-03-28 | — | — | US | disclosed |
| WO-2022115377-A1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC. (US) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101570-A1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | P2RX3 4784/4885P2RX2 4792/4885PTGS2 3282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.